keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
Published 7 months ago • 2.3K plays • Length 4:20Download video MP4
Download video MP3
Similar videos
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
9:02
phase 3 keynote-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early tnbc
-
4:17
keynote-522: efs sensitivity & subgroup analyses
-
0:57
a post hoc analysis of adjuvant radiation therapy in the keynote-522 study
-
2:53
neoadjuvant chemoimmunotherapy: keynote-522, i-spy & more
-
8:05
keynote-522: immune therapy and chemotherapy in patients with early triple negative breast cancer
-
1:43
dr. rugo on the results of the keynote-522 trial in tnbc
-
0:43
management of residual disease in triple negative breast cancer
-
1:39
encouraging developments in triple negative breast cancer immunotherapy
-
0:56
pembrolizumab as adjuvant therapy for tnbc
-
3:49
keynote-522: neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs place...
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer